About Ratio’s Technology Platforms
Ratio Therapeutics’ fully integrated proprietary R&D platforms, Trillium™ and Macropa™, harness the tumor-killing power of the alpha emitting radionuclide actinium-225 to selectively destroy cancer cells.
Trillium™
Ratio’s Trillium™ technology is a proprietary and innovative platform that incorporates a tunable, structural motif enabling our compounds to reversibly bind to albumin, thereby modulating their pharmacokinetics (PK) and improving drug availability, tumor delivery, and tumor loading, while simultaneously reducing the side effects commonly observed with other radiotherapies.
Macropa™
Ratio’s Macropa™ technology reflects a proprietary chelator that is used to attach the alpha emitting radionuclide actinium-225 to Trillium™ and other compounds. Its unique chemistry enables ease of manufacture and improves in vivo stability of the resulting compound. Macropa™ can be used with a wide variety of compounds, from small molecules to peptides and even large polypeptides, such as antibodies.
The combination of these platforms enables the tumor-killing power of alpha particles with potential for first- and best-in-class radiopharmaceuticals
